Organogenesis reported that its second Phase 3 randomized controlled trial of ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, did not meet the pre-specified primary endpoint versus saline at six months on the WOMAC pain scale. The study showed a numerical advantage of ReNu with a treatment difference of -0.51 and a one-sided p-value of 0.039, short of the one-sided p=0.023 threshold. The first Phase 3 trial had previously met the primary endpoint with a -0.72 difference and a one-sided p=0.0177. Baseline pain reduction at six months improved in the second trial compared with the first (-6.9 vs -6.0 for ReNu), and safety remained favorable. The company plans to seek a pre-BLA meeting with the FDA by the end of October, proposing a combined efficacy analysis across Phase 3 trials. ReNu holds the RMAT designation and has been evaluated across three RCTs totaling more than 1,300 patients.
The data package tests how far the FDA will stretch on symptomatic OA in the face of high placebo responses and modest between-arm deltas. If a pooled analysis anchored by one statistically positive trial and one narrowly negative trial is deemed sufficient—bolstered by RMAT and consistent safety—ReNu could become one of the first BLA-approved amniotic-derived injectables for OA, moving an orthobiologic category long associated with heterogeneous practices into a regulated therapeutic framework. That would be a meaningful precedent for birth-tissue products seeking full biologic approval rather than relying on 361 HCT/P pathways.
The stakes are clear across stakeholders. Patients and clinicians are stuck between NSAIDs, corticosteroid injections with durability and cartilage concerns, contested hyaluronic acid coverage, and a long runway to joint replacement. A single intra-articular biologic with a clean safety profile and even incremental pain relief would be additive, particularly for more severe subgroups where surgical deferral has real value. Payers, however, will scrutinize effect size and durability, compare against saline’s substantial placebo effect in injection trials, and demand evidence that outcomes reach minimal clinically important differences and reduce downstream costs. For competitors, this is a signal that the FDA may accept well-controlled, pooled symptomatic endpoints in OA if the totality of evidence is consistent, potentially accelerating BLA-grade development in orthobiologics while raising the bar above cash-pay or off-label paradigms.
The readout also sits at the intersection of several industry currents. Orthobiologics are moving from a fragmented, clinic-driven market toward tighter FDA oversight, with the window of enforcement discretion for unapproved birth-tissue products now behind the sector. RMAT designation migrating beyond oncology and rare diseases into high-burden musculoskeletal conditions underscores the agency’s willingness to engage—without lowering evidentiary standards on clinical benefit. At the same time, payer retrenchment on hyaluronic acid and the stalling of anti-NGF antibodies have reopened a window for safer symptomatic options, even as macro trends like GLP-1–driven weight loss may begin to bend OA prevalence and severity curves over time. Medical Affairs teams will need to marshal subgroup analyses, responder rates, functional outcomes, and pragmatic RWE to translate any approval into coverage and adoption.
The next inflection is regulatory: will FDA accept a pooled analysis with one success and one near-miss in a high-placebo domain, and if so, under what labeling and postmarketing commitments? Commercial success will hinge just as much on coding, J‑code timing, and Medicare contractor policies as on p-values. The strategic question for the sector is whether ReNu can convert a borderline efficacy signal into a reimbursable standard of care—and, if it does, whether that unlocks a broader BLA pathway for orthobiologics in degenerative joint disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
